<DOC>
	<DOCNO>NCT00555321</DOCNO>
	<brief_summary>The purpose clinical research study evaluate effect belatacept , relative tacrolimus , incidence rejection , graft loss death subject receive liver transplant</brief_summary>
	<brief_title>Belatacept Liver Transplant Recipients</brief_title>
	<detailed_description />
	<mesh_term>Tacrolimus</mesh_term>
	<mesh_term>Basiliximab</mesh_term>
	<mesh_term>Abatacept</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<criteria>First time recipient decease donor liver transplant Age 1870 Hepatitis C virus ( HCV ) positive recipient For Longterm extension studySubjects complete one year study treatment ( Week 52 ) Target Disease Exclusions : Donor Exclusions ) Living donor b ) ABOincompatible donor recipient pair c ) Donor age &lt; 12 &gt; 65 year ) Non heartbeating donor e ) Anticipated cold ischemia time &gt; 14 hour f ) Donor Disease ) Known Human immunodeficiency virus ( HIV ) infection ii ) Hepatitis B virus ( HBV ) surface antigenpositive polymerase chain reaction ( PCR ) positive donor HBV negative recipient iii ) HCV antibodypositive PCR positive donor HCV negative recipient Recipient Exclusions g ) Subjects history hypercoagulable state h ) Subjects fulminant hepatic failure ) Subjects receive split reduce liver j ) Subjects EpsteinBarr virus ( EBV ) negative Medical History Concurrent Diseases 1 . Subjects receive 2 consecutive week dialysis 1 month prior enrollment OR anticipate prolonged dialysis posttransplantation 2 . Subjects know intrinsic renal disease ( e.g. , urine protein/ creatinine ratio &gt; 150 mg/g presence abnormal number red blood cell ( RBCs ) granular cast urine ) AND calculate GFR &lt; 40 ml/min/1.73 m^2 body surface area ( BSA ) ( abbreviate Modification Diet Renal Disease [ MDRD ] ) . Subjects must calculate GFR assessment within 1 month prior enrollment . 3 . Subjects know HIV 4 . Subjects prior concurrent solid organ ( e.g. , heart , kidney , pancreas ) cell ( e.g. , islet , bone marrow ) transplant subject deem likely second solid organ cell transplant ( e.g. , islet , bone marrow ) within next 3 year . 5 . Subjects history cancer within last 5 year Allergies Adverse Drug Reactions ) Hypersensitivity medication use protocol Prohibited Treatments and/or Therapies 1 . Subjects receive immunosuppressive agent ( ) ( e.g. , methotrexate , abatacept , infliximab , etanercept , chemotherapy , etc . ) within past 6 month indication autoimmune disease 2 . Subjects receive maintenance corticosteroid dose &gt; 5 mg/day prednisone ( equivalent ) least 7 consecutive day within prior year underlie chronic inflammatory autoimmune disease 3 . Subjects use investigational drug within 30 day prior Day 1 visit 4 . Subjects previously treat belatacept</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>September 2012</verification_date>
</DOC>